Clinical Trial: Pembrolizumab dose-optimization study with Regression discontinuity design In patients with non-small cell lung Cancer to avert Excessive toxicity and cost (PRICE): Sub-study (Japan)

Tokyo, Aug. 27 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062700) titled 'Pembrolizumab dose-optimization study with Regression discontinuity design In patients with non-small cell lung Cancer to avert Excessive toxicity and cost (PRICE): Sub-study' on Aug. 27.

Study Type: Observational

Primary Sponsor: Institute - Public Health Research Foundation

Condition: Condition - Non-Small Cell Lung Cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - In patients enrolled in the PRICE trial who meet all the eligibility criteria for this sub-study, to measure the plasma concentrations of pembrolizumab and conduct an exploratory analysis to ...